Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…
Read more
  • 0

Enzyme engineering firm Codexis names new CEO 

Codexis (Nasdaq:CDXS) has announced that its board of directors has appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, to be its president and CEO.

Dilly will assume the role on August 9, 2022.

Former CEO John Nicols will retire to spend more time with his family. Nichols will continue to serve on the Codexis board until June 2023. Nichols also intends to work as a strategic advisor to the company for multiple years.

Dilly has held several senior roles in the pharmaceutical and biotech industries since the late 1980s. Firms he has worked for include SmithKline Beecham, Genentech, Chiron BioPharma and Aimmune Therapeutics.

Most recently, Dilly was the president and CEO of Sierra Oncology (Nasdaq: SRRA), which GlaxoSmithKline recently acquired for $1.9 billion.

“We are delighted that Stephen will serve as Codexis’ next CEO. He is a proven leader with a long track record of success building innovative companies,” said John Nicols, Pre…

Read more
  • 0